Remove 2030 Remove Patients Remove Side effects
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes. This is especially beneficial as a way of decreasing potential side effects.

article thumbnail

Lilly has a new blockbuster

World of DTC Marketing

Will patients, who are obese and don’t have Type 2 diabetes, ask for the drug for weight loss, and will patients understand the risks? Mounjaro, Lilly’s new diabetes drug, is sure to be in high demand initially after launch, but patients should be aware of its side effects. A matter of trust?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.

article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

A Harvard study found that almost half of Americans are expected to be obese by 2030, accounting for up to 18 percent of healthcare spending on related conditions, ranging from heart disease and stroke to osteoarthritis. . It has to persuade patients to sign up for some heinous side effects. Then there is the price.

article thumbnail

MHRA warns of serious eye-related adverse events after Dupixent use

Pharmaceutical Technology

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

article thumbnail

Could first anti-tau therapy be approved for Alzheimer’s?

European Pharmaceutical Review

A Phase III trial evaluating TauRx Therapeutics’ oral drug hydromethylthionine mesylate (HMTM), a tau aggression inhibitor, showed the medication continued to improve cognition over a pre-treatment baseline in patients with early Alzheimer’s for the first time. The safety data from the trial was consistent with earlier trial data.

article thumbnail

Developing donanemab – balancing cost versus benefit

European Pharmaceutical Review

Anti-amyloid beta (Aβ) monoclonal antibody (mAb) donanemab is part of new class of amyloid targeting therapies, and while it can slow Alzheimer’s disease progression by four to seven months, NICE’s independent committee highlighted, they were uncertain about making it available for NHS patients. billion in 2030, respectively.”